TAC01-HER2 Therapy in HER2-Positive Solid Tumors

Benjamin L. Schlechter, MD, senior physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, discusses the future implications of TAC01-HER2 therapy in patients with HER2-positive solid tumors.

Watch the Video

The ongoing, phase 1/2 TACTIC-2 trial (NCT04727151) is evaluating the efficacy and safety of autologous TAC01-HER2 T-cell therapy in patients with HER2-positive breast, colorectal, gall bladder, gastroesophageal junction (GEJ), gastric, esophageal, lung, and ovarian cancers.

Interim findings from this trial, presented at the 2023 ASCO Annual Meeting, showed:

• 2 partial responses to the therapy:
  • 1 in a patient with refractory GEJ cancer
  • 1 in a patient with refractory gastric cancer
• For patients with gastric, GEJ, or esophageal cancer:
  • Disease control rate (DCR): 83%
  • Overall response rate: 33%
• In heavily pretreated patients, the DCR was 67%.
• Adverse effects:
  • 1 dose-limiting toxicity (DLT), grade 3 pneumonitis,
  • 1 patient with grade 3 cytokine release syndrome.
• No incidence of immune effector cell–associated neurotoxicity syndrome has been reported.